San Diego's Otonomy pulled off a $100 million Wall Street debut, lining its pockets as it works to get a late-stage ear treatment through the FDA and onto the market.
A bioengineering professor says he has developed nanoparticles that can carry cancer-fighting insect toxins directly to tumors, sparing the rest of the body from nasty side effects, including damage to the heart, bleeding underneath the skin and unwanted clotting.
Researchers at the University of Washington have developed a medicated, electrospun fabric that could prevent HIV infections in women.
Researchers say they successfully tested in mice a molecular implant that contains gene-based mechanisms for delivering insulin based on feedback from an associated pH biosensor. By maintaining a healthy pH level between 7.35 and 7.45, the therapy, consisting of different genes and proteins, would prevent potentially fatal metabolic shock (ketoacidosis) in diabetics.
Prosensa, one of a handful of biotechs racing to develop treatments for Duchenne muscular dystrophy, has secured $7 million from a nonprofit to accelerate its R&D efforts.
Pfizer is reaching out to the Google-backed genomics outfit 23andMe to better understand the root causes of inflammatory bowel disease, looking to mine patient data for clues that could bolster its growing pipeline.
Australian entrepreneur Glenn Bilby helped found Quick Posture, a software for Microsoft's Xbox Kinect that can diagnose and help doctors manage movement-related diseases such as Parkinson's disease and multiple sclerosis.
Ophthalmology company Oraya Therapeutics will collaborate with researchers from Boston's Dana-Farber Cancer Institute to study applications of its novel radiation therapy against cancer when used in conjunction with gold nanoparticles.
Calico, Google's first major foray into biotech, has been quietly filling its ranks and fleshing out its mission in the months since its existence first came to light, bringing together industry luminaries to tackle the broad issue of aging.
Researchers have developed and are pilot testing an imaging pen that uses three different spectroscopic mechanisms to view a skin lesion. The device has the potential to identify suspected skin cancer tumors earlier and cut the costs of unnecessary biopsies.